| Drug General Information |
| Drug ID |
D04QGH
|
| Drug Name |
Piragliatin
|
| Synonyms |
GK2; R1440; RO4389620
|
| Drug Type |
Small molecular drug
|
| Indication |
Unspecified
|
Investigative |
[1]
|
|---|
| Therapeutic Class |
Endocrine, nutritional and metabolic diseases
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H20ClN3O4S
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Glucokinase |
Target Info |
Modulator |
|
|---|
|
KEGG Pathway
|
Glycolysis / Gluconeogenesis
|
|
Galactose metabolism
|
|
Starch and sucrose metabolism
|
|
Amino sugar and nucleotide sugar metabolism
|
|
Butirosin and neomycin biosynthesis
|
|
Metabolic pathways
|
|
Biosynthesis of antibiotics
|
|
Carbon metabolism
|
|
Insulin signaling pathway
|
|
Insulin secretion
|
|
Prolactin signaling pathway
|
|
Glucagon signaling pathway
|
|
Type II diabetes mellitus
|
|
Maturity onset diabetes of the young
|
|
Central carbon metabolism in cancer
|
|
Pathway Interaction Database
|
FOXA2 and FOXA3 transcription factor networks
|
|
HIF-1-alpha transcription factor network
|
|
PathWhiz Pathway
|
Nucleotide Sugars Metabolism
|
|
Starch and Sucrose Metabolism
|
|
Galactose Metabolism
|
|
Trehalose Degradation
|
|
Reactome
|
Regulation of gene expression in beta cells
|
|
Glucose transport
|
|
Glycolysis
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Glycolysis and Gluconeogenesis
|
|
MAPK Signaling Pathway
|
|
Regulation of beta-cell development
|
|
Metabolism of carbohydrates
|
|
Hexose transport
|
| References |
| REF 1 | Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.J Clin Endocrinol Metab.2010 Nov;95(11):5028-36. |
|---|
